Viveve Medical, Inc.

Welcome to the Vavid Third Quarter 2022 Financial Results in Corporate Update Conference Call. All participants will be in listening mode. If you need assistance, please signal a conference specialist by pressing the star key followed by zero. Please note that this event is recorded. I'll turn the call over to Ms. Jeanne Sundell of Vavid, Senior Director of Corporate Communications. Please go ahead.

Thank you, Operator, and welcome, everyone. Before we begin, we would like to remind you that this conference call may contain forward-looking statements regarding future events or the future financial performance of the company. Any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the corporation's cost, timing, progress, and results of its clinical trials, including the initiation, progress of, and results from our pursuit trial, and whether the clinical trial will support the intended uses for treatment of stress urinary incontinence in the United States, fluctuation of global market economic conditions, impact of COVID-19 on clinical development, regulatory review and clearances, manufacturing, system placements and utilization, projections, expectations, plans, beliefs, and prospects. These statements are based on judgments and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are described more fully in the company's annual report on Form 10-K and other filings made with the SEC, which are also available on the company's website. Also, any forward-looking statements represent management's view only as of the date of this conference call and should not be relied upon as representing management's views as of any subsequent date. Speaking on the call today will be Scott Durbin, the VEEDS Chief Executive Officer, and Jim Robbins, Senior Vice President of Finance and Administration. I will now turn the call over to Jim.

Thank you, Jeanne. Good afternoon, everyone, and thank you for joining the call today. I will begin today's call with a brief review of our third quarter 2022 financial results. I will then turn the call over to Scott, who will provide a corporate update. Today, we reported total revenue for the third quarter of $1.7 million from the global sale of 11 systems and approximately 3,100 disposable treatment kits. As of the end of the third quarter 2022, the company had an installed base of 915 PV systems worldwide. Third quarter total operating expenses were $5.2 million compared to $5.6 million for the same period last year. The decrease is primarily due to reduced clinical study costs during the period as we advanced our fully enrolled pursuit trial. Operating expense reductions were partially offset by costs associated with increased engineering and development work related to our next generation products and strategic planning efforts in anticipation of the pursuit clinical trial completion. As of September 30th, 2022, we reported cash and cash equivalents of $5.9 million. Thanks. I'll now turn the conference call over to Scott.